Le rapport du groupe de travail sur les effets thérapeutiques des deux enthéogènes.

La conclusion:« We conclude that MDMA and psilocybin may show promise in highly selected populations but only where these medicines are administered in closely clinically supervised settings and with intensive professional support. »